Specific Treatment Exists for SARS-CoV-2 ARDS
Open Access
- 10 June 2021
- Vol. 9 (6), 635
- https://doi.org/10.3390/vaccines9060635
Abstract
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), seems to be difficult to overcome. A pandemic of such a scale has not been seen since the 1918 influenza pandemic. Although the predominant clinical presentation is respiratory disease, neurological manifestations and sequelae are increasingly being recognized. We observed a case series of rapid recovery of ARDS within 24 h in the preliminary clinical features of COVID-19 ARDS-associated neurological disease. It was also noted that by 15 April, 2021, there was no SARS-CoV-2 ARDS on Sorok Island in South Korea, where lepers had been living together. We compared each of dapsone’s effects on humans and considered those of SARS-CoV-2. Dapsone showed different effects in the brain. The Sorokdo National Hospital reported a relationship between dapsone and the neuroinflammasome of Alzheimer’s disease (AD) in Sorok Island from January 2005 to June 2020. AD prevalence was low in the leprosy patient group who took dapsone regularly. The preliminary cross-sectional study of the trial group (22 subjects) and the control group (22 subjects) in the Hunt Regional Hospital reported the following results: The chi-square statistic is 5.1836. The p-value is 0.022801. The result is considered significant at p < 0.05. The results from the medical treatment from 21 December to 29 December 2020 were considered. The mortality rates at the ARDS onset stage were 0% with dapsone administered as a standard COVID-19 treatment and 40% without dapsone administered as a standard COVID-19 treatment, respectively. Based on the respiratory failure and sudden high death rate originating from the involvement of the brainstem, especially the pre-Bötzinger complex, dapsone can be used to significantly reduce the incidence of the cases of acute respiratory distress syndrome and other illnesses caused by SARS-CoV-2.Keywords
Other Versions
This publication has 70 references indexed in Scilit:
- Amyloid β Levels in Human Red Blood CellsPLOS ONE, 2012
- Why dapsone stops seizures and may stop neutrophils’ delivery of VEGF to glioblastomaBritish Journal of Neurosurgery, 2012
- Hypersensitivity Reactions to Dapsone: A Systematic ReviewActa Dermato-Venereologica, 2012
- A Geometric and Electronic Study of DapsoneJournal of Computational and Theoretical Nanoscience, 2011
- Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System InfectionsClinical Microbiology Reviews, 2010
- Innovative Use of DapsoneDermatologic Clinics, 2010
- Regulation of P-glycoprotein and other ABC drug transporters at the blood–brain barrierTrends in Pharmacological Sciences, 2010
- Complete atrioventricular block associated with dapsone therapy: a rare complication of dapsone-induced hypersensitivity syndromeJournal of Clinical Pharmacy & Therapeutics, 2009
- Dapsone penetrates cerebrospinal fluid during Pneumocystis carinii pneumonia prophylaxisDiagnostic Microbiology and Infectious Disease, 1996
- Oxidation of methionyl residues in proteins: Tools, targets, and reversalFree Radical Biology & Medicine, 1995